ES2037086T3 - Procedimiento para preparar formulaciones farmaceuticas. - Google Patents

Procedimiento para preparar formulaciones farmaceuticas.

Info

Publication number
ES2037086T3
ES2037086T3 ES198787306731T ES87306731T ES2037086T3 ES 2037086 T3 ES2037086 T3 ES 2037086T3 ES 198787306731 T ES198787306731 T ES 198787306731T ES 87306731 T ES87306731 T ES 87306731T ES 2037086 T3 ES2037086 T3 ES 2037086T3
Authority
ES
Spain
Prior art keywords
procedure
pharmaceutical formulations
preparing pharmaceutical
present
cimetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787306731T
Other languages
English (en)
Spanish (es)
Inventor
Brian Anthony Christopher Carlin
Graham Stanley Leonard
John Norman Charles Healey
Geoffrey David Tovey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Application granted granted Critical
Publication of ES2037086T3 publication Critical patent/ES2037086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES198787306731T 1986-08-01 1987-07-29 Procedimiento para preparar formulaciones farmaceuticas. Expired - Lifetime ES2037086T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868618847A GB8618847D0 (en) 1986-08-01 1986-08-01 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2037086T3 true ES2037086T3 (es) 1993-06-16

Family

ID=10602097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787306731T Expired - Lifetime ES2037086T3 (es) 1986-08-01 1987-07-29 Procedimiento para preparar formulaciones farmaceuticas.

Country Status (22)

Country Link
US (1) US4996222A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0257823B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0643304B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960012397B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1024497C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU601206B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1287802C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3778795D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK149988D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG18388A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2037086T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8618847D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005298T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU205853B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE60759B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL83349A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY100998A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH23505A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT85468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1988000825A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA875631B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZW (1) ZW13587A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
CA2172807C (en) * 1994-08-01 1999-10-12 Keith S. Lienhop Tastemasked liquid pharmaceutical delivery system
GB9504599D0 (en) * 1995-03-03 1995-04-26 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
GB2298365B (en) * 1995-03-03 1997-05-07 Reckitt & Colmann Prod Ltd A liquid pharmaceutical composition alginate and potassium bicarbonate
PL194696B1 (pl) * 1997-04-30 2007-06-29 Reckitt Benckiser Healthcare Kompozycja w stałej postaci dawkowania zawierająca alginiany
GB9708772D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions
IN186245B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6515008B1 (en) * 2000-05-04 2003-02-04 Smithkline Beecham Corporation Formulation
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
US20050008660A1 (en) * 2003-03-10 2005-01-13 The Regents Of The University Of Michigan Compositions and methods for use of alginate dural sealants
JP2008518593A (ja) * 2004-11-02 2008-06-05 ピュラック バイオケム ビー．ブイ． 乳の中のタンパク質を安定させ且つタンパク質の凝固を予防する方法
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
EP1745775B1 (en) * 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
MX2012002831A (es) * 2009-09-10 2012-05-08 Bial Portela & Ca Sa Formulaciones para suspension oral de acetato de esclicarbazepina.
EP3528848A4 (en) * 2016-10-19 2020-07-15 Signpath Pharma Inc. PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS CAUSING CANALOPATHIES
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104868A (en) * 1980-01-24 1981-08-20 Fujimoto Seiyaku Kk Conversion between polymorphous crystals of cimetidine
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine

Also Published As

Publication number Publication date
US4996222A (en) 1991-02-26
HU205853B (en) 1992-07-28
KR880701551A (ko) 1988-11-03
HUT46541A (en) 1988-11-28
GR3005298T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-24
PT85468A (en) 1987-08-01
EP0257823A1 (en) 1988-03-02
ZW13587A1 (en) 1989-02-15
AU7756487A (en) 1988-02-24
WO1988000825A1 (en) 1988-02-11
CN87105387A (zh) 1988-02-17
IE60759B1 (en) 1994-08-10
PT85468B (pt) 1990-06-29
AU601206B2 (en) 1990-09-06
IE872077L (en) 1988-02-01
JPH0643304B2 (ja) 1994-06-08
PH23505A (en) 1989-08-16
JPH01500434A (ja) 1989-02-16
MY100998A (en) 1991-06-29
ZA875631B (en) 1989-03-29
GB8618847D0 (en) 1986-09-10
EP0257823B1 (en) 1992-05-06
KR960012397B1 (ko) 1996-09-20
CA1287802C (en) 1991-08-20
CN1024497C (zh) 1994-05-18
IL83349A (en) 1992-03-29
EG18388A (en) 1992-10-30
DK149988A (da) 1988-03-18
DK149988D0 (da) 1988-03-18
DE3778795D1 (de) 1992-06-11

Similar Documents

Publication Publication Date Title
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
CS653586A3 (en) Pharmaceutical containing 7-isopropoxyisoflavone
ES2191034T3 (es) Formulaciones de liberacion controlada para la liberacion de metoprolol durante 24 horas.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2189803T3 (es) Procedimiento.
ES2084944T3 (es) Amidas terapeuticas.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
JO1502B1 (en) New pharmacy vehicles
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
GR3006091T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
ATE99945T1 (de) Verwendung von 5'-deoxy-5'-methylthioadenosin s- adenosylmethionin und dessen salzen zur herstellung von seborrhea vermindernden arzneimitteln.
ES2091183T3 (es) Metodo para mejorar el sueño.
GB2021409A (en) Pharmaceutical composition
ES2160582T3 (es) Capsula dura de ocfosfato de citarabina.
MY101916A (en) Etoposide oral dosage form.
GB1480441A (en) Compositions for treating nicotine poisoning
IT8567725A0 (it) Li contengono derivati 1-sostituiti del 4-metossi-2,3,6-trimetilbenzene loro procedimento di preparazione e composizioni medicamentose e cosmetiche che
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
JPS6438073A (en) Novel derivative of tetrahydropyridine, manufacture and intermediate, use as drug and medicinal composition
ES2016052A6 (es) Procedimiento para preparar derivados de adenosinmonofosfonato (amp) ciclico y de guanosinmonofosfonato (gmp) ciclico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 257823

Country of ref document: ES